BetterLife Pharma Inc (NPAU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BetterLife Pharma Inc (NPAU) has a cash flow conversion efficiency ratio of 0.030x as of July 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-172.31K ≈ $-201.45K USD) by net assets (€-5.81 Million ≈ $-6.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NPAU equity to assets ratio to measure how much of total assets are equity-financed.
BetterLife Pharma Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how BetterLife Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BetterLife Pharma Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
BetterLife Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BetterLife Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Me Group International PLC
LSE:MEGP
|
0.180x |
|
Wickes Group PLC
LSE:WIX
|
1.293x |
|
Eng Kah Corporation Bhd
KLSE:7149
|
0.048x |
|
Careteq Ltd
AU:CTQ
|
-0.265x |
|
Adalta Ltd
AU:1AD
|
2.240x |
|
Bioatla Inc
NASDAQ:BCAB
|
0.141x |
|
BRITANNIA LIFE SCIENCES
F:L020
|
0.057x |
|
Eezy PLC
HE:EEZY
|
0.056x |
Annual Cash Flow Conversion Efficiency for BetterLife Pharma Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of BetterLife Pharma Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see how much is BetterLife Pharma Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | €-7.36 Million ≈ $-8.61 Million |
€-2.02 Million ≈ $-2.36 Million |
0.275x | -14.52% |
| 2024-01-31 | €-7.70 Million ≈ $-9.00 Million |
€-2.47 Million ≈ $-2.89 Million |
0.321x | +60.97% |
| 2023-01-31 | €-7.53 Million ≈ $-8.81 Million |
€-1.50 Million ≈ $-1.76 Million |
0.200x | -93.09% |
| 2022-01-31 | €-3.88 Million ≈ $-4.54 Million |
€-11.20 Million ≈ $-13.10 Million |
2.887x | +85.82% |
| 2021-01-31 | €-4.61 Million ≈ $-5.39 Million |
€-7.16 Million ≈ $-8.38 Million |
1.553x | +152.37% |
| 2020-01-31 | €2.66 Million ≈ $3.11 Million |
€-7.88 Million ≈ $-9.21 Million |
-2.966x | -121.11% |
| 2019-01-31 | €3.51 Million ≈ $4.10 Million |
€-4.71 Million ≈ $-5.50 Million |
-1.342x | -113.38% |
| 2018-01-31 | €-55.99K ≈ $-65.46K |
€-561.52K ≈ $-656.48K |
10.029x | +5290.49% |
| 2017-01-31 | €-1.93 Million ≈ $-2.26 Million |
€-359.45K ≈ $-420.23K |
0.186x | -- |
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the t… Read more